---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000008"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:40:15.431019+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics appoints Charles Newton to Board; Carl Gordon resigns effective March 9, 2026

## Summary
- Carl Gordon, Ph.D., resigned from the Board and Compensation Committee, effective March 9, 2026; no disagreement with the Company.
- Charles Newton appointed as Class III director, effective March 9, 2026, and will serve on Compensation and Audit Committees.
- Newton is former CFO of Lyell Immunopharma and has held senior roles at Bank of America, Credit Suisse, and Morgan Stanley.
- Newton currently serves on the boards of Novavax, Inc. and Coherus Oncology, Inc.

## SEC filing metadata
- accession: 0001664710-26-000008
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000008/0001664710-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000008/kros-20260220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000008
- JSON: https://secwatch.observer/filing/0001664710-26-000008.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.